Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in ...

Although data from The New England Journal of Medicine published in November 2024 confirmed that inebilizumab (Uplizna, Amgen) significantly reduced the risk for IgG4-related disease (IgG4-RD ...

With sales of $91 million, Uplizna came up $20 million short of the consensus projection. Meanwhile, Krystexxa’s haul of $236 million was $57 million shy of expectations, and Tepezza’s $381 ...

As Amgen waits for an FDA decision on a second indication for its B cell-depleting therapy Uplizna, it has new data suggesting a third may be coming down the pipe. New data from the phase 3 MINT ...

Horizon Therapeutics Plc presented positive new MRI data from the phase 3 clinical trial of UPLIZNA (inebilizumab) at the 9th Congress of the European Academy of Neurology (EAN) in Budapest ...

At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.

Turning to rare disease. Our four key growth drivers: TEPEZZA, KRYSTEXXA, UPLIZNA and TAVNEOS, are all early in their life cycles and well positioned for long-term growth. UPLIZNA is a ...

Turning to rare disease. UPLIZNA recently launched as the first FDA-approved therapy for IgG4-related disease, and we're now on track for a December 14th PDUFA date in generalized myasthenia gravis.